- Page 1: Pulmonary Hypertension:Beyond the S
- Page 6 and 7: Independent Predictor of Mortality
- Page 8 and 9: Etiology• Noxious stimuli exposur
- Page 10 and 11: Components
- Page 12 and 13: Pathways Implicated in PHTNTXA2Pre
- Page 14 and 15: Components• Prostacyclin- Prostag
- Page 16 and 17: Abnormalities in CoagulationPlatele
- Page 18 and 19: Pathophysiology• Increased flow-
- Page 20 and 21: Pathophysiology• Low resistance,
- Page 22 and 23: Pathophysiology ProgressionDeath
- Page 24 and 25: ClassificationARTERIAL• Idopathic
- Page 26 and 27: ARTERIAL HYPERTENSION
- Page 28 and 29: Pulmonary Arterial Hypertension•
- Page 30 and 31: Collagen Vascular Disease• Sclero
- Page 32 and 33: Portopulmonary HTN• Portal HTN +
- Page 34 and 35: Methamphetamine• Amphetamine, met
- Page 36 and 37: VENOUS HYPERTENSION
- Page 38 and 39: Left Heart Disease• LV systolic d
- Page 40 and 41: LV Pressure‐Volume Curvehttp://ww
- Page 42 and 43: Congenital Heart Disease• Systemi
- Page 44 and 45: PHTN associated with lungdisease/hy
- Page 46 and 47: Thromboembolic Disease• Thromboem
- Page 48 and 49: Miscellaneous• Sarcoidosis• His
- Page 50 and 51: SYMPTOMSAnd then I felttired…
- Page 52 and 53: Signs and Symptoms• Dyspnea- Most
- Page 54 and 55:
Physical Exam• Prominent, split,
- Page 56 and 57:
ECG Changes• Right‐axis deviati
- Page 58 and 59:
CXRwww.emedicine.com/RADIO/topic583
- Page 60 and 61:
V/Q Scanwww.emedicine/RADIO/topic58
- Page 62 and 63:
Echohttp://www.emedicine.com/med/im
- Page 64 and 65:
DIAGNOSIS
- Page 66 and 67:
Diagnostic Tests• BNP- Increased
- Page 68 and 69:
Vasoreactivity Testing• RHC• Va
- Page 70 and 71:
Management Goals• Improve functio
- Page 72 and 73:
Nocturnal Desaturationwww.rnceus.co
- Page 74 and 75:
Digoxin• Controversial- No mortal
- Page 76 and 77:
Specific Concerns with Anticoagulat
- Page 78 and 79:
Treatment For LV sided Heart Diseas
- Page 80 and 81:
Action of Current PHTN TherapiesTXA
- Page 82 and 83:
Survival and Prostacyclin• 162 pa
- Page 84 and 85:
The ‘Other’ Prostacyclin Analog
- Page 86 and 87:
Phosphodiesterase Inhibitors• Inh
- Page 88 and 89:
Action of Current PHTN TherapiesPre
- Page 90 and 91:
Endothelin Receptor Antagonists•
- Page 92 and 93:
Nitric Oxide• Increases intracell
- Page 94 and 95:
Nitric Oxide• Vascular effects- D
- Page 96 and 97:
Weaning Nitric Oxide• Case Study
- Page 98 and 99:
Surgical Options• Pulmonary Endar
- Page 100 and 101:
Pulmonary Endartectomywww.emedicine
- Page 102 and 103:
FUTURE THERAPIES
- Page 104 and 105:
Action of PHTN TherapiesTXA2Pre‐P
- Page 106 and 107:
Serotonin Antagonists• “Treatme
- Page 108 and 109:
More Hope…• Perhaps the inhibit
- Page 110 and 111:
You knew this next one was coming
- Page 112 and 113:
CONCLUSIONSThe End
- Page 114 and 115:
WorkUp• Autoantibody tests, HIV t
- Page 116 and 117:
One More Thought…• …most of t
- Page 118 and 119:
References• Herve, P., Launay, J.
- Page 120:
References• Nagaya, N., Nishikimi